The Role of the TROP2 Biomarker in Cancer

𝗔𝗜 𝗠𝗘𝗘𝗧𝗦 𝗢𝗡𝗖𝗢𝗟𝗢𝗚𝗬: 𝗛𝗢𝗪 𝗥𝗢𝗖𝗛𝗘'𝗦 𝗧𝗥𝗢𝗣𝟮 𝗗𝗜𝗔𝗚𝗡𝗢𝗦𝗧𝗜𝗖 𝗖𝗢𝗨𝗟𝗗 𝗥𝗘𝗩𝗢𝗟𝗨𝗧𝗜𝗢𝗡𝗜𝗭𝗘 𝗡𝗦𝗖𝗟𝗖 𝗖𝗔𝗥𝗘

Navigating the clinical impact of TROP2-targeting in NSCLC

HER2 ADC or TROP2 ADC in HR+/HER2- MBC? Prof. Giuseppe Curigliano Responds

Choosing CDX Models for HER2, TROP-2, Nectin-4, and TOP1 ADC Programs

How Clinicians Choose Between TROP2 ADCs

Saiama Waqar, MD, MSCI: Targeting Trop-2: Advances in Antibody-Drug Conjugates

Trop−2 ADC Safety Profile: A Head-to-Head Comparison of Key AEs and Management

【がん免疫療法】TROP2の壁とPAR-2の隠蔽工作 ― ICIが効くための前提条件 ― SCCC最新医学AI解析（2026年4月16日）（通常速8分47秒/2倍速4分30秒）

Community Perspective: ADCs and Novel Agents in TNBC

Drs. Schalper, Press, Tarantino & Wainberg discuss #HER2, #HER3, & #TROP2: https://bit.ly/37BH4Ek

Why TRO-Breast02 Included Higher-Risk ‘Bad Actors’

Breakthrough Data in Metastatic TNBC with Drs. Mark Pegram & Ana Garrido-Castro

Metastatic TNBC cannot wait

TROPION-Lung01 Final OS: Datopotamab Deruxtecan vs Docetaxel in NSCLC | OA08.03

ADC Integration in Breast & Lung Cancer: The Role of Dato-DXd with Drs. Neil Iyengar & Ticiana Leal